Immutep Ltd
Recommendation: Buy
Entry Date - 22 Aug, 25
-
IMM
-
Buy
-
AUD 0.247
-
AUD 0.25935
-
AUD 0.27417
-
47 days
-
Closed
-
21.46%
Key Highlights
AUD 0.27417 |
Buy |
| Ticker | IMM.AU |
| Price | AUD 0.39 |
| Market Cap | AUD 574.05M |
| BookValue | AUD 0.098 |
| Volume | 5129824 |
| 52 Week High | AUD 0.2225 |
| 52 Week Low | AUD 0.2225 |
Data Powered by EOD Historical Data (“EODHD”).
Company Overview
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Stock Performance
Data Powered by EOD Historical Data (“EODHD”).
Key Financials
| Year Ending June | FY23A | FY24A | FY25A |
|---|---|---|---|
| Revenue (AUD MM)1130720.00 | 1.13M | - | - |
| EBITDA (AUD MM) | - | - | - |
| EBITDA Margin (%) | % | ||
| Net Profit (AUD MM) | -39.89635M | ||
| Net Profit Margin (%) | -35.28% | ||
| Net Profit Margin (%) | |||
| EPS (AUD) | 0.00 -0.04 0.00 | 0.00 0.00 -0.03 | -0.05 0.00 |
Data Powered by EOD Historical Data (“EODHD”)
Key Investment Highlights
Key Positives
Key Negatives
Data Source: REFINITIV, Analysis: StockNextt
Key Investment Risks
Recommendation Summary
Technical Summary
| Entry Price | Support* | Target 1** | Target 2** |
|---|---|---|---|
| 0.247 | 0.2223 | 0.25935 | 0.27417 |
Data Source: REFINITIV, Analysis: StockNextt
*Support can be considered as an indicative stop-loss, and if prices move below that level on closing basis individuals may evaluate exiting the position depending on their risk appetite, previous holdings, and other factors considered. The support and resistance levels may need to be re-evaluated within 4-6 weeks’ time frame depending on the stock price movements from the date of recommendation on the stock.
**Target prices may vary by ±0.5% depending on market volatility.
Key Financials in Pictures
Income Statement
Balance Sheet
Change in Cash
Total Operating Cash
Dividends Paid
Data Powered by EOD Historical Data (“EODHD”).
Peer Comparison
Sector: Basic Materials Industry: Agricultural Inputs
| Company | Change ($) | Price ($) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) |
|---|---|---|---|---|---|---|
| CF CF Industries Holdings Inc |
10.23% 6.70 | 421.75 | 7.16 | 2.22 | 3.63 | 1.35 |
| CTVA Corteva Inc |
10.23% 6.70 | 421.75 | 7.16 | 2.22 | 3.63 | 1.35 |
| NTR Nutrien Ltd |
10.23% 6.70 | 421.75 | 7.16 | 2.22 | 3.63 | 1.35 |
| MOS The Mosaic Company |
10.23% 6.70 | 421.75 | 7.16 | 2.22 | 3.63 | 1.35 |
| YARIY Yara International ASA |
10.23% 6.70 | 421.75 | 7.16 | 2.22 | 3.63 | 1.35 |
Data Powered by EOD Historical Data (“EODHD”).
Disclosures:
Related Risks: This report may be looked at from high-risk perspective and recommendations are provided are for a short duration. Recommendations provided in this report are solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels as on August 22, 2025. The reference data in this report has been partly sourced from REFINITIV.
Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.
Note 4: Kalkine reports are prepared based on the stock prices captured either from REFINITIV or Trading View. Typically, REFINITIV or Trading View may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.
Technical Indicators Defined: -
Support:
A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.
Target:
A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Target 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Target 2 may act as the crucial resistance level for the stock.
Stop-loss:
It is a level to protect further losses in case of unfavourable movement in the stock prices.
Disclaimer :
This report (“Report”) has been issued by RIAAA Technologies Pty Ltd ABN 43 008 181 379 (Australian financial services licence number 259983) and prepared by RIAAA Technologies Pty Ltd and its related bodies corporate who are authorised to provide general financial product advice. https://stocknextt.com/au
nd its associated pages are published by RIAAA Technologies Pty Ltd.
Any advice provided in this Report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate for your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred in this Report. You should obtain a copy of the relevant Offer Document and consider it before making any decision about whether to acquire the security or financial product.
RIAAA Technologies Pty Ltd strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any of the general advice in this Report or on the RIAAA Technologies Pty Ltd website. Not all investments are appropriate for all people.
The information in this Report and on the RIAAA Technologies Pty Ltd website has been prepared from a wide variety of sources, which RIAAA Technologies Pty Ltd, to the best of its knowledge and belief, considers accurate. RIAAA Technologies Pty Ltd has made every effort to ensure the reliability of the information contained in its reports (including this Report), newsletters and websites. All information represents our views at the date of publication and may change without notice.
The information in this Report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations to invest in securities and other financial products. RIAAA Technologies Pty Ltd is not responsible for, and does not guarantee, the performance of, or returns on, any investments mentioned in this Report.
RIAAA Technologies Pty Ltd does not issue, sell or deal in any financial products.
This Report may contain information on past performance of particular investments. Past performance is not a reliable indicator of future performance. Returns stated do not take into account transaction costs and taxes. To the extent permitted by law, and excluding any dishonesty or gross negligence by RIAAA Technologies Pty Ltd, RIAAA Technologies Pty Ltd disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Report, the RIAAA Technologies Pty Ltd website and any information published on the RIAAA Technologies Pty Ltd website without any warranties or representations by RIAAA Technologies Pty Ltd to you. To the extent the law prohibits or limits this exclusion, RIAAA Technologies Pty Ltd limits its liability to the resupply of services.
Please also read our Terms and conditions and Financial Services Guide for further information. Employees and/or associates of RIAAA Technologies Pty Ltd and its related entities may hold interests in the securities or other financial products covered in this Report or on the RIAAA Technologies Pty Ltd website. Any such employees and associates are required to comply with certain, procedures and disclosures as required by law.
Kalkine Media Pty Ltd, an affiliate of RIAAA Technologies Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this Report.
Copyright 2025 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this report, or its content, may be reproduced in any form without our prior consent.